Who
Peter Scott Chin
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Denali Therapeutics.
In numbers
- Trades disclosed
- 2
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $74K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Sep 2026
- Last trade
- 4 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 9 Sep 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K1,654 at $22.29 | filing |
| 4 Sep 2026filed 9 Sep 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K1,654 at $22.29 | filing |
News
Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Has Average Price Target of $35.85DNLI · dailypolitical.com · 25 Oct 2026Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026DNLI · manilatimes.net · 22 Oct 2026Denali Therapeutics (NASDAQ:DNLI) vs. Century Therapeutics (NASDAQ:IPSC) Head-To-Head ContrastDNLI · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Peter Scott Chin; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.